BCYC - Bicycle Therapeutics Ltd Stock Price, Fair Value and News

22.53USD-0.36 (-1.57%)Market Closed

Market Summary

USD22.53-0.36

Market Closed

-1.57%

BCYC Alerts

Big jump in Revenue (Y/Y)

Losses in recent quarter

BCYC Stock Price

View Fullscreen

BCYC RSI Chart

BCYC Valuation

Market Cap

960.5M

Price/Earnings (Trailing)

-5.71

Price/Sales (Trailing)

23.08

EV/EBITDA

-3.41

Price/Free Cashflow

-11.18

BCYC Price/Sales (Trailing)

BCYC Profitability

EBT Margin

-400.00%

Return on Equity

-47.23%

Return on Assets

-30.73%

Free Cashflow Yield

-8.95%

BCYC Fundamentals

BCYC Revenue

Revenue (TTM)

41.6M

Rev. Growth (Yr)

298.9%

Rev. Growth (Qtr)

266.35%

BCYC Earnings

Earnings (TTM)

-168.2M

Earnings Growth (Yr)

32%

Earnings Growth (Qtr)

45.9%

Breaking Down BCYC Revenue

Last 7 days

-3.3%

Last 30 days

1.0%

Last 90 days

5.3%

Trailing 12 Months

-6.7%

How does BCYC drawdown profile look like?

BCYC Financial Health

Current Ratio

10.42

Debt/Equity

0.09

Debt/Cashflow

-2.76

BCYC Investor Care

Shares Dilution (1Y)

41.96%

Diluted EPS (TTM)

-4.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	41.6M	0	0	0
2023	15.5M	22.5M	24.8M	27.0M
2022	13.7M	16.3M	15.0M	14.5M
2021	11.1M	11.3M	11.8M	11.7M
2020	8.5M	8.6M	11.8M	10.4M
2019	10.7M	10.6M	9.6M	13.8M
2018	3.3M	4.6M	5.9M	7.1M
2017	0	0	0	2.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Bicycle Therapeutics Ltd

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 18, 2024	baker bros. advisors lp	acquired	-	-	24,000	-
Apr 11, 2024	hannay michael charles ferguson	sold	-5,779	22.49	-257	chief prod & supply chain off
Apr 03, 2024	crockett nigel	sold	-22,738	23.81	-955	chief business officer
Apr 03, 2024	milnes alistair	sold	-22,738	23.81	-955	chief operating officer
Apr 03, 2024	keen nicholas	sold	-18,809	23.81	-790	chief scientific officer
Apr 03, 2024	lee kevin	sold	-75,192	23.81	-3,158	chief executive officer
Apr 03, 2024	thompson travis alvin	sold	-3,619	23.81	-152	chief accounting officer
Apr 03, 2024	skynner michael	sold	-22,738	23.81	-955	chief technology officer
Feb 20, 2024	sands stephen h.	acquired	-	-	12,000	-
Feb 06, 2024	arroyo santiago	acquired	-	-	21,660	chief development officer

Which funds bought or sold BCYC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	OSAIC HOLDINGS, INC.	reduced	-29.95	-1,265	34,585	-%
May 10, 2024	CITIGROUP INC	reduced	-99.18	-279,367	3,187	-%
May 10, 2024	Rubric Capital Management LP	unchanged	-	1,400,980	5,115,030	0.15%
May 10, 2024	BlackRock Inc.	added	14.63	5,248,900	14,318,200	-%
May 10, 2024	PNC Financial Services Group, Inc.	added	1.85	55,046	191,730	-%
May 10, 2024	JPMORGAN CHASE & CO	added	54.25	205,425	388,141	-%
May 10, 2024	L & S Advisors Inc	added	393	1,067,240	1,251,470	0.14%
May 10, 2024	WESTFIELD CAPITAL MANAGEMENT CO LP	added	13.26	9,284,180	25,869,000	0.14%
May 10, 2024	GROUP ONE TRADING, L.P.	reduced	-99.65	-472,587	2,266	-%
May 09, 2024	TOCQUEVILLE ASSET MANAGEMENT L.P.	reduced	-25.27	12,337	434,505	0.01%

Are Funds Buying or Selling BCYC?

Are funds buying BCYC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BCYC

No. of Funds

Unveiling Bicycle Therapeutics Ltd's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 18, 2024	baker bros. advisors lp	19.9%	7,689,243	SC 13D
Feb 14, 2024	jefferies financial group inc.	165%	1,948,000	SC 13G
Feb 14, 2024	deep track capital, lp	9.25%	3,490,506	SC 13G/A
Feb 14, 2024	paradigm biocapital advisors lp	9.8%	3,707,001	SC 13G/A
Feb 14, 2024	ridgeback capital investments l.p.	2.2%	844,235	SC 13G/A
Feb 12, 2024	janus henderson group plc	0.0%	0	SC 13G/A
Feb 12, 2024	baker bros. advisors lp	12.8%	4,823,598	SC 13G
Jul 20, 2023	gsk plc	4.4%	1,529,561	SC 13D/A
Feb 24, 2023	paradigm biocapital advisors lp	5.4%	1,610,665	SC 13G
Feb 14, 2023	deep track capital, lp	9.50%	2,819,045	SC 13G/A

Recent SEC filings of Bicycle Therapeutics Ltd

View All Filings

Date Filed	Form Type	Document
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 22, 2024	4	Insider Trading
Apr 18, 2024	3	Insider Trading
Apr 18, 2024	8-K	Current Report
Apr 18, 2024	DEFA14A	DEFA14A
Apr 18, 2024	SC 13D	13D - Major Acquisition
Apr 15, 2024	DEF 14A	DEF 14A
Apr 15, 2024	ARS	ARS
Apr 12, 2024	4	Insider Trading

Peers (Alternatives to Bicycle Therapeutics Ltd)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Bicycle Therapeutics Ltd News

Latest updates

Bicycle Therapeutics Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	266.3%	19,530,000	5,331,000	5,352,000	11,397,000	4,896,000	3,185,000	3,040,000	4,378,000	3,860,000	3,771,000	4,333,000	1,785,000	1,808,000	3,848,000	3,842,000	1,571,000	1,129,000	5,281,000	614,000	1,522,000	6,384,000
Operating Expenses	-14.0%	51,246,000	59,566,000	56,149,000	54,508,000	46,699,000	35,396,000	32,799,000	31,678,000	31,243,000	21,794,500	18,627,000	19,062,000	17,832,000	20,907,000	14,517,000	14,154,000	12,772,000	10,045,000	10,867,000	9,510,000	9,678,000
S&GA Expenses	-100.0%	-	14,869,000	16,281,000	14,788,000	14,488,000	10,677,000	10,047,000	11,824,000	16,959,000	8,840,500	8,114,000	7,340,000	8,139,000	10,851,500	7,154,000	6,196,000	4,998,000	3,396,000	4,789,000	2,973,000	3,402,000
R&D Expenses	-22.0%	34,864,000	44,697,000	39,868,000	39,720,000	32,211,000	24,719,000	22,752,000	19,854,000	14,284,000	12,954,000	10,513,000	11,722,000	9,693,000	10,056,000	7,363,000	7,958,000	7,774,000	6,649,000	6,078,000	6,537,000	6,276,000
EBITDA Margin	40.1%	-3.76	-6.28	-6.09	-5.89	-7.60	-7.41	-6.42	-5.14	-5.47	-5.48	-5.55	-5.40	-4.98	-4.81	-	-	-	-	-	-	-
Interest Expenses	0.1%	821,000	820,000	814,000	821,000	808,000	826,000	817,000	883,000	818,000	820,000	823,000	819,000	522,000	-	-	-	-	-	-	-	-
Income Taxes	-226.8%	-400,000	315,500	2,300,000	-517,000	-600,000	-455,000	-238,000	-400,000	-400,000	-755,500	-415,000	-200,000	-300,000	-55,000	-500,000	-97,000	-107,000	-138,000	-331,000	135,000	80,000
Earnings Before Taxes	44.8%	-26,913,000	-48,779,000	-47,626,000	-43,120,000	-39,682,000	-30,398,000	-28,585,000	-27,275,000	-27,983,000	-18,785,000	-15,093,000	-18,073,000	-16,531,000	-17,488,000	-10,603,000	-12,212,000	-11,431,000	-4,544,000	-9,813,000	-10,082,000	-6,423,000
EBT Margin	39.8%	-4.00	-6.64	-6.48	-6.30	-8.13	-7.90	-6.82	-5.45	-5.81	-5.85	-5.71	-5.56	-5.13	-4.98	-	-	-	-	-	-	-
Net Income	45.9%	-26,563,000	-49,099,000	-49,898,000	-42,603,000	-39,064,000	-29,978,000	-28,347,000	-26,828,000	-27,564,000	-18,037,000	-14,678,000	-17,913,000	-16,191,000	-17,433,000	-10,138,000	-12,115,000	-11,324,000	-4,406,000	-9,482,000	-10,217,000	-6,503,000
Net Income Margin	39.7%	-4.04	-6.70	-6.51	-6.22	-8.01	-7.79	-6.70	-5.33	-5.69	-5.71	-5.62	-5.47	-5.05	-4.91	-	-	-	-	-	-	-
Free Cashflow	-49.7%	-70,881,000	-47,339,000	-1,527,000	33,819,000	-48,510,000	-31,757,000	-8,855,000	-33,330,000	-31,156,000	-11,502,000	21,549,000	-12,541,000	-14,330,000	-17,101,000	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	-8.1%	547	595	639	454	429	411	417	445	460	480	281	226	224	161	170	119	129	110	116	126	82.00
Current Assets	-8.2%	516	562	603	408	381	369	381	408	430	459	273	218	215	156	164	113	123	104	110	120	77.00
Cash Equivalents	-13.1%	458	526	572	340	294	339	361	373	407	439	260	199	196	136	150	97.00	110	92.00	96.00	109	63.00
Net PPE	-11.9%	13.00	15.00	16.00	18.00	18.00	19.00	16.00	17.00	9.00	3.00	2.00	2.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Liabilities	-14.8%	191	224	223	234	186	140	128	134	129	134	111	84.00	82.00	66.00	61.00	48.00	47.00	17.00	21.00	22.00	29.00
Current Liabilities	-28.8%	50.00	70.00	70.00	72.00	53.00	53.00	42.00	41.00	35.00	36.00	30.00	23.00	21.00	23.00	17.00	17.00	16.00	9.00	9.00	9.00	9.00
Long Term Debt	0.3%	31.00	31.00	31.00	31.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	29.00	15.00	14.00	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	31.00	31.00	31.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	29.00	15.00	14.00	-	-	-	-	-	-
Shareholder's Equity	-4.0%	356	371	416	220	243	271	289	311	330	346	171	142	142	95.00	110	71.00	82.00	93.00	95.00	105	-
Retained Earnings	-5.2%	-538	-511	-462	-412	-370	-331	-301	-272	-245	-218	-200	-185	-167	-151	-134	-124	-111	-100	-96.14	-86.66	-69.94
Additional Paid-In Capital	1.3%	895	883	875	633	613	601	590	584	578	568	374	331	313	250	246	199	197	195	194	193	2.00
Shares Outstanding	0.5%	43.00	42.00	42.00	31.00	30.00	30.00	30.00	30.00	30.00	25.00	24.00	23.00	22.00	19.00	-	-	-	-	-	-	-
Float	-	-	-	-	767	-	-	-	490	-	-	-	718	-	-	-	190	-	-	-	114	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-49.9%	-70,869	-47,288	-1,025	34,096	-46,411	-30,309	-5,871	-23,531	-26,400	-10,435	21,718	-12,370	-13,707	-16,617	-9,985	-12,349	21,162	-4,919	-10,885	-7,608	-5,201
Share Based Compensation	18.8%	9,282	7,812	7,430	8,193	9,042	5,540	5,368	5,673	10,198	2,999	2,688	2,575	3,821	1,564	1,510	1,319	2,121	1,083	819	905	276
Cashflow From Investing	76.5%	-12.00	-51.00	-502	-277	-2,099	-1,448	-2,984	-9,799	-4,756	-1,067	-169	-171	-623	-484	-95.00	-301	-320	-391	-283	-463	-418
Cashflow From Financing	384.7%	1,871	386	234,631	12,292	2,718	5,888	159	195	450	190,664	40,450	15,552	74,059	1,744	61,087	10.00	2.00	122	-811	59,095	34.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BCYC Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Condensed Consolidated Statements of Operations and Comprehensive Loss
Collaboration revenues	$ 19,530	$ 4,896
Operating expenses:
Research and development	34,864	32,211
General and administrative	16,382	14,488
Total operating expenses	51,246	46,699
Loss from operations	(31,716)	(41,803)
Other income (expense):
Interest income	5,624	2,929
Interest expense	(821)	(808)
Total other income (expense), net	4,803	2,121
Net loss before income tax provision	(26,913)	(39,682)
Benefit from income taxes	(350)	(618)
Net loss	$ (26,563)	$ (39,064)
Net loss per share, basic	$ (0.62)	$ (1.30)
Net loss per share, diluted	$ (0.62)	$ (1.30)
Weighted average ordinary shares outstanding, basic	42,560,091	30,001,725
Weighted average ordinary shares outstanding, diluted	42,560,091	30,001,725
Comprehensives loss:
Net Income (Loss)	$ (26,563)	$ (39,064)
Other comprehensive income:
Foreign currency translation adjustment	526	(316)
Total comprehensive loss	$ (26,037)	$ (39,380)

BCYC Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 456,997	$ 526,423
Prepaid expenses and other current assets	19,903	11,406
Research and development incentives receivable	39,062	24,039
Total current assets	515,962	561,868
Property and equipment, net	12,788	14,515
Operating lease right-of-use assets	12,025	13,169
Other assets	6,368	5,792
Total assets	547,143	595,344
Current liabilities:
Accounts payable	7,061	13,050
Accrued expenses and other current liabilities	26,029	31,509
Deferred revenue, current portion	16,420	24,978
Total current liabilities	49,510	69,537
Long-term debt, net of discount	30,802	30,698
Operating lease liabilities, net of current portion	8,048	9,382
Deferred revenue, net of current portion	98,127	110,216
Other long-term liabilities	4,608	4,579
Total liabilities	191,095	224,412
Commitments and contingencies (Note 11)
Shareholders' equity:
Ordinary shares, including non-voting ordinary shares, £0.01 nominal value; 61,876,165 and 59,612,613 shares authorized on March 31, 2024 and December 31, 2023, respectively; 42,632,597 and 42,431,766 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	553	550
Additional paid-in capital	894,596	883,446
Accumulated other comprehensive loss	(778)	(1,304)
Accumulated deficit	(538,323)	(511,760)
Total shareholders' equity	356,048	370,932
Total liabilities and shareholders' equity	$ 547,143	$ 595,344

About Bicycle Therapeutics Ltd

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. It is developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; BT5528, a BTC that is in a Phase I/II clinical trial targeting Ephrin type-A receptor 2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA; and BT7401, a multivalent CD137 agonist. In addition, it collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, dementia, central nervous system, neuromuscular, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca AB, Sanofi, Oxurion NV, and the Dementia Discovery Fund, as well as with Ionis Pharmaceuticals, Inc.; and a discovery collaboration and license agreement with Genentech Inc. for the discovery and development of Bicycle peptides for multiple immuno-oncology targets, as well as strategic collaboration with Bayer for developing Novel Targeted Radionuclide Therapies in Oncology. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

WEBSITE	bicycletherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	236

Bicycle Therapeutics Ltd Frequently Asked Questions

What is the ticker symbol for Bicycle Therapeutics Ltd? What does BCYC stand for in stocks?

BCYC is the stock ticker symbol of Bicycle Therapeutics Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bicycle Therapeutics Ltd (BCYC)?

As of Mon May 13 2024, market cap of Bicycle Therapeutics Ltd is 960.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BCYC stock?

You can check BCYC's fair value in chart for subscribers.

What is the fair value of BCYC stock?

You can check BCYC's fair value in chart for subscribers. The fair value of Bicycle Therapeutics Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bicycle Therapeutics Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BCYC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bicycle Therapeutics Ltd a good stock to buy?

The fair value guage provides a quick view whether BCYC is over valued or under valued. Whether Bicycle Therapeutics Ltd is cheap or expensive depends on the assumptions which impact Bicycle Therapeutics Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCYC.

What is Bicycle Therapeutics Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, BCYC's PE ratio (Price to Earnings) is -5.71 and Price to Sales (PS) ratio is 23.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BCYC PE ratio will change depending on the future growth rate expectations of investors.